Advertisement
Advertisement
ACAD
Acadia Pharmaceuticals Inc.
22.33
USDSponsored
+0.13
+0.60%
Apr 06, 16:00 UTC -4
Closed
After-Market
22.33
0.00
-0.02%
ACAD Earnings Reports
Positive Surprise Ratio
ACAD beat 27 of 41 last estimates.
66%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$289.15M
/$0.07
Implied change from Q4 25 (Revenue/ EPS)
+1.82%
/-95.63%
Implied change from Q1 25 (Revenue/ EPS)
+18.35%
/-36.36%
Acadia Pharmaceuticals Inc. earnings per share and revenue
On Feb 25, 2026, ACAD reported earnings of 1.60 USD per share (EPS) for Q4 25, beating the estimate of 0.13 USD, resulting in a 1044.49% surprise. Revenue reached 283.99 million, compared to an expected 298.42 million, with a -4.84% difference. The market reacted with a -1.32% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of 0.07 USD, with revenue projected to reach 289.15 million USD, implying an decrease of -95.63% EPS, and increase of 1.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
FAQ
What were Acadia Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Acadia Pharmaceuticals Inc. reported EPS of $1.60, beating estimates by 1044.49%, and revenue of $283.99M, -4.84% below expectations.
How did the market react to Acadia Pharmaceuticals Inc.'s Q4 2025 earnings?
The stock price moved down -1.32%, changed from $24.97 before the earnings release to $24.64 the day after.
When is Acadia Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Acadia Pharmaceuticals Inc.'s next earnings report?
Based on 7
analysts, Acadia Pharmaceuticals Inc. is expected to report EPS of $0.07 and revenue of $289.15M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement